Pretty sure you already know this by now, considering the results of recent phase 1 and phase 3 trials. Here, the results of a phase 2 trial are presented in the New England Journal of Medicine.
This article has got a great figure 1 – worth presenting if you’re looking to summarise the impact vemurafenib will have on melanoma treatment. Overall survival duration was almost 16 months – and importantly, cutaneous SCCs occurred in just over a quarter of patients.
Read it here.
image | NCI
source | NEJM